ReviewAntioxidants & redox signaling2019
From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.
Review in Antioxidants & redox signaling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.Frontiers in pharmacology · 2023Pooled it
- Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.Frontiers in cardiovascular medicine · 2022Pooled it
- Exploring the nexus: Clinical and physiological correlation between cardiovascular disease and colorectal cancer.Experimental physiology · 2026Review
- Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Protective effects of biomimetic Cu-Zn-MOF against DOX-Induced cardiotoxicity through inhibiting oxidative stress and ferroptosis.Journal of nanobiotechnology · 2025Article
- Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025Review
- A Case of Ventricular Arrhythmia in a Patient With HER2-Positive Gastric Cancer Receiving Trastuzumab.Case reports in gastrointestinal medicine · 2025Article
- Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches.Frontiers in cardiovascular medicine · 2025Review
- Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies.Cancer communications (London, England) · 2024Review
- PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Evaluation of skeletal muscle function in male rats with doxorubicin-induced myopathy following various exercise techniques: the significant role of glucose transporter 4.Pflugers Archiv : European journal of physiology · 2024Article
- Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis.Clinical Medicine Insights. Oncology · 2024Article
- Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.Frontiers in oncology · 2024Review
- A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines.Frontiers in pharmacology · 2024Review
- Advances in research on molecular markers in immune checkpoint inhibitor-associated myocarditis.Cancer innovation · 2023Review
- Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children.Pharmaceutics · 2023Review
- Article
- Gender Differences in Oxidative Stress in Relation to Cancer Susceptibility and Survival.Antioxidants (Basel, Switzerland) · 2023Review
- Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.Cancers · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.